A5012483727- Head and Neck Cancer Studies
- Advanced Radiotherapy Techniques
- Cancer Diagnosis and Treatment
- Oral health in cancer treatment
- Head and Neck Surgical Oncology
- Brain Metastases and Treatment
- Prostate Cancer Diagnosis and Treatment
- Ear and Head Tumors
- Breast Cancer Treatment Studies
- Medical Imaging Techniques and Applications
- Salivary Gland Tumors Diagnosis and Treatment
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Bladder and Urothelial Cancer Treatments
- Dysphagia Assessment and Management
- Salivary Gland Disorders and Functions
- Breast Lesions and Carcinomas
- Colorectal and Anal Carcinomas
- Medical Imaging and Analysis
- Esophageal Cancer Research and Treatment
- Management of metastatic bone disease
- Radiation Therapy and Dosimetry
- Tracheal and airway disorders
- Ophthalmology and Eye Disorders
- Pituitary Gland Disorders and Treatments
University of Turin
2006-2024
A. O. Ordine Mauriziano di Torino
2016-2023
Johnson University
2021
Rutgers, The State University of New Jersey
2021
Ospedale San Luigi Gonzaga
2010-2019
Fondazione Ricerca Molinette
1993-2000
Azienda Ospedaliero Universitaria San Giovanni Battista
1999
Azienda Sanitaria Locale di Asti
1994
Background: Oropharyngeal mucositis occurs in virtually all patients with head and neck cancer receiving radiochemotherapy. The manipulation of the oral cavity microbiota represents an intriguing challenging target. Patients Methods: A total 75 were enrolled to receive Lactobacillus brevis CD2 lozenges or care regimen sodium bicarbonate mouthwashes. primary endpoint was incidence grade 3 4 oropharyngeal during radiotherapy treatment. Results: There no statistical difference 3-4 between...
The objective of this study was to assess the utility CT-MRI image fusion software and compare both prostate volume localization with CT MRI studies. We evaluated differences in clinical volumes patients undergoing three-dimensional conformal radiation therapy for localized cancer. After several tests performed ensure quality software, eight suffering from adenocarcinoma were submitted studies treatment position within an immobilization device before start radiotherapy. target (CTV)...
ObjectiveDelineation of treatment volumes is a major source uncertainties in radiotherapy (RT). This also true for rectal cancer patients undergoing neoadjuvant RT, with potential impact on quality. We investigated the role digital platform Anatom-e (Anatom-e Information Sytems Ltd., Houston, Texas) increasing compliance to follow specific protocol multicentric setting.Materials and methodsTwo clinical cases locally advanced were chosen. Participants instructed 2009 Radiation Therapy...
Aim and background Radiotherapy is the conventional treatment for locally advanced inoperable head neck squamous cell carcinoma. However, poor therapeutic results justify development of radiochemotherapy combinations. In an attempt to improve local control survival in patients with stage III IV unresectable carcinoma based on our previous dose escalation study, we undertook a prospective multicentric randomized trial. Materials methods From November 1992 through December 1995, total 164 were...
Bladder cancer (BC) has a typical aetiology characterized by multistep carcinogenesis due to environmental exposures, genetic susceptibility, and their interaction. Several lines of evidence suggest that DNA repair plays role in the development progression BC. In particular, study individual susceptibility double strand breaks (DSBs) may provide valuable information on BC risk, help identify those patients at high-risk either recurrence or disease, possibly personalizing both surveillance...
The authors report their experience on the treatment of 28 cases middle ear (3) and external auditory meatus (EAM) cancers (25) with surgery and/or radiation therapy. According to histologic type, there were 23 squamous cell carcinomas, 4 basal carcinomas 1 adenocystic carcinoma.Surgery alone was performed in 2 cases, combined radiotherapy 11 15 cases. Postoperative therapy dose ranged between 4500 5500 cGy; definitive 6000-7000 cGy. median follow-up 61 months.Complete response rate 6 weeks...